Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Primary result · HbA1cResult — go to the resultMean difference −0.32 percentage points 95% CI −0.33 to −0.30Authors' conclusion
In people with preexisting cardiovascular disease and overweight or obesity but without diabetes, long-term semaglutide increases regression to biochemical normoglycemia and reduces progression to biochemical diabetes but does not slow glycemic progression over time.
Study context
- Population
- Adults aged ≥45 years with BMI ≥27 kg/m² and preexisting CVD but without diabetes (HbA1c <6.5%)
- Participants
- 17,604 adults
- Comparison
- Semaglutide 2.4 mg weekly vs placebo
- Semaglutiden = 8,803
- Placebon = 8,801reference
- Primary endpoint
- Major glycemic outcomes: HbA1c, proportions achieving biochemical normoglycemia (HbA1c <5.7%) and progressing to biochemical diabetes (HbA1c ≥6.5%)
Methodological detailsmulticentre, double-blind, Mean ± SD intervention exposure 152 ± 56 weeks; follow-up 176 ± 40 weeks
- Multicentre
- Double-blind
- Mean ± SD intervention exposure 152 ± 56 weeks; follow-up 176 ± 40 weeks
Primary result
HbA1c · after nadir at 20 weeks, throughout study
Mean difference
−0.32 percentage points
95% CI −0.33 to −0.30
P < 0.0001
Semaglutidevs Placebo
mean difference −0.32 percentage points (95% CI −0.33 to −0.30); P < 0.0001
As reported in the abstract
Further findings
Progression to biochemical diabetes (HbA1c ≥6.5%) · by week 156
P < 0.0001
Number needed to treat to prevent a case of diabetes
- NNT to prevent a case of diabetes
- 18.5
Body weight · plateau at 65 weeks
- Body weight lower with semaglutide
- 8.9%
Mediation by weight reduction
- Share of progression mediated by magnitude of weight reduction
- 24.5%
- Share of regression mediated by magnitude of weight reduction
- 27.1%
- Regression and progression dependent on baseline glycemia
Original publication
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care. Published 22 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →